AIM ImmunoTech Inc. [AMEX: AIM] gained 8.72% or 0.15 points to close at $1.87 with a heavy trading volume of 2752750 shares. The company report on November 25, 2020 that AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2.
First, AIM reports that Roswell Park Comprehensive Cancer Center’s Phase 1/2a study evaluating the two-drug combination of AIM’s Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19 is fully underway, with the first patient enrolled and treated on the study.
It opened the trading session at $1.77, the shares rose to $1.93 and dropped to $1.75, the range by which the price of stock traded the whole day. The daily chart for AIM points out that the company has recorded -20.43% loss over the past six months. However, it is still -334.88% lower than its most recent low trading price.
If we look at the average trading volume of 1.90M shares, AIM reached to a volume of 2752750 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AIM ImmunoTech Inc. [AIM]:
The Average True Range (ATR) for AIM ImmunoTech Inc. is set at 0.10, with the Price to Sales ratio for AIM stock in the period of the last 12 months amounting to 374.00. The Price to Book ratio for the last quarter was 1.21, with the Price to Cash per share for the same quarter was set at 0.99.
Trading performance analysis for AIM stock
AIM ImmunoTech Inc. [AIM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.47. With this latest performance, AIM shares dropped by -3.11% in over the last four-week period, additionally sinking by -20.43% over the last 6 months – not to mention a rise of 300.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIM stock in for the last two-week period is set at 50.02, with the RSI for the last a single of trading hit 53.93, and the three-weeks RSI is set at 48.07 for AIM ImmunoTech Inc. [AIM]. The present Moving Average for the last 50 days of trading for this stock 1.9860, while it was recorded at 1.7920 for the last single week of trading, and 2.3645 for the last 200 days.
AIM ImmunoTech Inc. [AIM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AIM ImmunoTech Inc. [AIM] shares currently have an operating margin of -8831.43 and a Gross Margin at -537.86. AIM ImmunoTech Inc.’s Net Margin is presently recorded at -6809.29.
Return on Total Capital for AIM is now -81.38, given the latest momentum, and Return on Invested Capital for the company is -71.87. Return on Equity for this stock declined to -105.45, with Return on Assets sitting at -16.18. When it comes to the capital structure of this company, AIM ImmunoTech Inc. [AIM] has a Total Debt to Total Equity ratio set at 49.43. Additionally, AIM Total Debt to Total Capital is recorded at 33.08, with Total Debt to Total Assets ending up at 10.02. Long-Term Debt to Equity for the company is recorded at 50.52, with the Long-Term Debt to Total Capital now at 31.77.
Reflecting on the efficiency of the workforce at the company, AIM ImmunoTech Inc. [AIM] managed to generate an average of -$366,654 per employee. Receivables Turnover for the company is 0.15 with a Total Asset Turnover recorded at a value of 0.00.AIM ImmunoTech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 50.00 and a Current Ratio set at 50.00.
AIM ImmunoTech Inc. [AIM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, AIM ImmunoTech Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 64.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AIM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AIM ImmunoTech Inc. go to 25.00%.
An analysis of insider ownership at AIM ImmunoTech Inc. [AIM]
There are presently around $5 million, or 6.80% of AIM stock, in the hands of institutional investors. The top three institutional holders of AIM stocks are: MORGAN STANLEY with ownership of 805,415, which is approximately 69.094% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 502,692 shares of the stock with an approximate value of $0.86 million in AIM stocks shares; and VANGUARD GROUP INC, currently with $0.7 million in AIM stock with ownership of nearly 9.787% of the company’s market capitalization.
Positions in AIM ImmunoTech Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 27 institutional holders increased their position in AIM ImmunoTech Inc. [AMEX:AIM] by around 1,015,466 shares. Additionally, 7 investors decreased positions by around 135,944 shares, while 9 investors held positions by with 1,600,874 shares. The mentioned changes placed institutional holdings at 2,752,284 shares, according to the latest SEC report filing. AIM stock had 15 new institutional investments in for a total of 478,125 shares, while 6 institutional investors sold positions of 98,985 shares during the same period.